Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study

David Lang,1,2 Wolfgang Haslinger,2 Kaveh Akbari,2,3 Mario Scala,2,3 Benedikt Hergan,2,3 Christian Asel,2,3 Andreas Horner,1,2 Romana Wass,1,2 Elmar Brehm,1,2 Bernhard Kaiser,1 Bernd Lamprecht1,2 1Johannes Kepler University Hospital, Department of Pulmonology, Linz, Austria; 2Johannes Kepler Univers...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lang D, Haslinger W, Akbari K, Scala M, Hergan B, Asel C, Horner A, Wass R, Brehm E, Kaiser B, Lamprecht B
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	carcinoembryonic antigen platinum doublet chemotherapy pembrolizumab cyfra 21-1 recist nivolumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/de62df45ecee46c7bf7642e198ce9c9e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:de62df45ecee46c7bf7642e198ce9c9e
record_format	dspace
spelling	oai:doaj.org-article:de62df45ecee46c7bf7642e198ce9c9e2021-12-02T12:40:45ZSerum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study1179-2728https://doaj.org/article/de62df45ecee46c7bf7642e198ce9c9e2020-12-01T00:00:00Zhttps://www.dovepress.com/serum-tumor-marker-dynamics-as-predictive-biomarkers-in-nsclc-chemo-im-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728David Lang,1,2 Wolfgang Haslinger,2 Kaveh Akbari,2,3 Mario Scala,2,3 Benedikt Hergan,2,3 Christian Asel,2,3 Andreas Horner,1,2 Romana Wass,1,2 Elmar Brehm,1,2 Bernhard Kaiser,1 Bernd Lamprecht1,2 1Johannes Kepler University Hospital, Department of Pulmonology, Linz, Austria; 2Johannes Kepler University, Medical Faculty, Linz, Austria; 3Johannes Kepler University Hospital, Central Radiology Institute, Linz, AustriaCorrespondence: David LangKepler University Hospital, Department of Pulmonology, MedCampus III, Krankenhausstraße 9, Linz 4020, AustriaTel +43 5 7680 83 73797Email david.lang@kepleruniklinikum.atObjective: To evaluate serum tumor markers (STM) as predictive biomarkers in advanced non-small cell lung cancer (NSCLC) treated with chemo-immunotherapy.Methods: Patients having received platinum-based chemo-(CHT) and PD-1/PD-L1-directed immune checkpoint inhibitor (ICI) combination therapy were retrospectively followed. Carcinoembryonic antigen (CEA), carbohydrate antigen 19– 9 (CA19-9), cytokeratin-19 fragments (CYFRA 21– 1) and neuron specific enolase (NSE) were routinely measured at NSCLC diagnosis. The marker with the highest relative elevation was defined “leading STM”, its change was assessed between CHT-ICI as well as mono-ICI maintenance initiation and the respective subsequent restaging. Corresponding computed tomography evaluations were analyzed using response evaluation criteria in solid tumors (RECIST). For CHT-ICI combination and subsequent mono-ICI-maintenance therapy, leading STM and RECIST response were evaluated regarding progression-free (PFS) and overall survival (OS) in Kaplan–Meier analyses.Results: Among 80 CHT-ICI patients (41% women, mean age 63 years), median PFS was 5 months (M;4,9), median OS was 15M (10,/). PFS was significantly (p=0.042) longer, when the leading STM had decreased at first restaging under CHT-ICI combination therapy (9M (5,12; n=41) vs 5M (3,6; n=16)). In the 54 (67.5%) patients who received subsequent mono-ICI maintenance therapy, STM decrease was similarly associated with significantly (p< 0.001) longer PFS (16M (7,/; n=16) vs 3.5M (2,6; n=22)). Patients with radiologically stable or progressive disease and concomitant leading STM decrease had similar PFS in the CHT-ICI combination phase (4M (3,7; n=16) vs 4.5M (2,6; n=14)), but longer PFS in the mono-ICI maintenance setting (13M (7,16; n=10) vs 3M (2,4; n=17)). Median OS was not reached in most subgroups.Conclusion: Leading STM dynamics provide predictive biomarker information additional to radiological response evaluation patients receiving CHT-ICI combination therapy, especially in the mono-ICI maintenance setting.Keywords: carcinoembryonic antigen, platinum doublet chemotherapy, pembrolizumab, CYFRA 21-1, RECIST, nivolumabLang DHaslinger WAkbari KScala MHergan BAsel CHorner AWass RBrehm EKaiser BLamprecht BDove Medical Pressarticlecarcinoembryonic antigenplatinum doublet chemotherapypembrolizumabcyfra 21-1recistnivolumabNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 11, Pp 113-121 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	carcinoembryonic antigen platinum doublet chemotherapy pembrolizumab cyfra 21-1 recist nivolumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	carcinoembryonic antigen platinum doublet chemotherapy pembrolizumab cyfra 21-1 recist nivolumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Lang D Haslinger W Akbari K Scala M Hergan B Asel C Horner A Wass R Brehm E Kaiser B Lamprecht B Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study
description	David Lang,1,2 Wolfgang Haslinger,2 Kaveh Akbari,2,3 Mario Scala,2,3 Benedikt Hergan,2,3 Christian Asel,2,3 Andreas Horner,1,2 Romana Wass,1,2 Elmar Brehm,1,2 Bernhard Kaiser,1 Bernd Lamprecht1,2 1Johannes Kepler University Hospital, Department of Pulmonology, Linz, Austria; 2Johannes Kepler University, Medical Faculty, Linz, Austria; 3Johannes Kepler University Hospital, Central Radiology Institute, Linz, AustriaCorrespondence: David LangKepler University Hospital, Department of Pulmonology, MedCampus III, Krankenhausstraße 9, Linz 4020, AustriaTel +43 5 7680 83 73797Email david.lang@kepleruniklinikum.atObjective: To evaluate serum tumor markers (STM) as predictive biomarkers in advanced non-small cell lung cancer (NSCLC) treated with chemo-immunotherapy.Methods: Patients having received platinum-based chemo-(CHT) and PD-1/PD-L1-directed immune checkpoint inhibitor (ICI) combination therapy were retrospectively followed. Carcinoembryonic antigen (CEA), carbohydrate antigen 19– 9 (CA19-9), cytokeratin-19 fragments (CYFRA 21– 1) and neuron specific enolase (NSE) were routinely measured at NSCLC diagnosis. The marker with the highest relative elevation was defined “leading STM”, its change was assessed between CHT-ICI as well as mono-ICI maintenance initiation and the respective subsequent restaging. Corresponding computed tomography evaluations were analyzed using response evaluation criteria in solid tumors (RECIST). For CHT-ICI combination and subsequent mono-ICI-maintenance therapy, leading STM and RECIST response were evaluated regarding progression-free (PFS) and overall survival (OS) in Kaplan–Meier analyses.Results: Among 80 CHT-ICI patients (41% women, mean age 63 years), median PFS was 5 months (M;4,9), median OS was 15M (10,/). PFS was significantly (p=0.042) longer, when the leading STM had decreased at first restaging under CHT-ICI combination therapy (9M (5,12; n=41) vs 5M (3,6; n=16)). In the 54 (67.5%) patients who received subsequent mono-ICI maintenance therapy, STM decrease was similarly associated with significantly (p< 0.001) longer PFS (16M (7,/; n=16) vs 3.5M (2,6; n=22)). Patients with radiologically stable or progressive disease and concomitant leading STM decrease had similar PFS in the CHT-ICI combination phase (4M (3,7; n=16) vs 4.5M (2,6; n=14)), but longer PFS in the mono-ICI maintenance setting (13M (7,16; n=10) vs 3M (2,4; n=17)). Median OS was not reached in most subgroups.Conclusion: Leading STM dynamics provide predictive biomarker information additional to radiological response evaluation patients receiving CHT-ICI combination therapy, especially in the mono-ICI maintenance setting.Keywords: carcinoembryonic antigen, platinum doublet chemotherapy, pembrolizumab, CYFRA 21-1, RECIST, nivolumab
format	article
author	Lang D Haslinger W Akbari K Scala M Hergan B Asel C Horner A Wass R Brehm E Kaiser B Lamprecht B
author_facet	Lang D Haslinger W Akbari K Scala M Hergan B Asel C Horner A Wass R Brehm E Kaiser B Lamprecht B
author_sort	Lang D
title	Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study
title_short	Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study
title_full	Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study
title_fullStr	Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study
title_full_unstemmed	Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study
title_sort	serum tumor marker dynamics as predictive biomarkers in nsclc chemo-immunotherapy and mono-immunotherapy maintenance: a registry-based descriptive study
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/de62df45ecee46c7bf7642e198ce9c9e
work_keys_str_mv	AT langd serumtumormarkerdynamicsaspredictivebiomarkersinnsclcchemoimmunotherapyandmonoimmunotherapymaintenancearegistrybaseddescriptivestudy AT haslingerw serumtumormarkerdynamicsaspredictivebiomarkersinnsclcchemoimmunotherapyandmonoimmunotherapymaintenancearegistrybaseddescriptivestudy AT akbarik serumtumormarkerdynamicsaspredictivebiomarkersinnsclcchemoimmunotherapyandmonoimmunotherapymaintenancearegistrybaseddescriptivestudy AT scalam serumtumormarkerdynamicsaspredictivebiomarkersinnsclcchemoimmunotherapyandmonoimmunotherapymaintenancearegistrybaseddescriptivestudy AT herganb serumtumormarkerdynamicsaspredictivebiomarkersinnsclcchemoimmunotherapyandmonoimmunotherapymaintenancearegistrybaseddescriptivestudy AT aselc serumtumormarkerdynamicsaspredictivebiomarkersinnsclcchemoimmunotherapyandmonoimmunotherapymaintenancearegistrybaseddescriptivestudy AT hornera serumtumormarkerdynamicsaspredictivebiomarkersinnsclcchemoimmunotherapyandmonoimmunotherapymaintenancearegistrybaseddescriptivestudy AT wassr serumtumormarkerdynamicsaspredictivebiomarkersinnsclcchemoimmunotherapyandmonoimmunotherapymaintenancearegistrybaseddescriptivestudy AT brehme serumtumormarkerdynamicsaspredictivebiomarkersinnsclcchemoimmunotherapyandmonoimmunotherapymaintenancearegistrybaseddescriptivestudy AT kaiserb serumtumormarkerdynamicsaspredictivebiomarkersinnsclcchemoimmunotherapyandmonoimmunotherapymaintenancearegistrybaseddescriptivestudy AT lamprechtb serumtumormarkerdynamicsaspredictivebiomarkersinnsclcchemoimmunotherapyandmonoimmunotherapymaintenancearegistrybaseddescriptivestudy
_version_	1718393771422384128

Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study

Ejemplares similares